Manufacturing & Packaging

Platform is expected to streamline batch turnaround times

Acquisition of Texas facility to add 60,000 square feet of manufacturing space to company’s footprint

Provider will be CDMO’s primary material supplier in the lab, clinical, and production settings

Award given in recognition of CDMO’s commitment to promoting sustainable future

Phoenix location will be company’s first to focus on high-density microarrays for diagnostic and life science research

CDMO will be able to produce rAAV commercial grade product

Provides clientele with an augmented drug development solution

Provider’s regulatory affairs, pharmacovigilance services expected to help increase ABC’s portfolio

Collaboration aims to decrease environmental burden in the space

Lotte Biologics will assume facility ownership, as CDMO joins pharma space with the acquisition

With the new additions, CDMO expands its analytical testing and development services

Big Pharma to collaborate with researchers from A*STAR, along with Singapore universities

Will further boost CDMO’s injectable drug product platform

Can help facilitate digital identification of medications

Drug safety analysis to be conducted at Rockland, MD facility

Plant will be CDMO’s first standalone GMP and vaccine development manufacturing site in the country

Former Novartis plant will become mRNA manufacturing facility, the first in Singapore

Manufacturing plant addition features nine new processing suites

New microbial fermentation tech expected to boost CDMO’s overall capacity

Kaysersberg facility’s Lab+ deal expected to bolster CDMO’s filling services

Non-exclusive deal intends to popularize RTU containment solutions within pharma industry

Center implements Industry 4.0 principles

Invests $5 million to upgrade manufacturing processes

ACC supports both clinical and commercial viral vector production

Expansion project addresses assay development demands

Organization’s PAI portfolio boosts drug R&D, process development for pharma manufacturers

Project is centered around drug substance manufacturing

P4 is partially operational in under two years

Strategies to boost the reproducibility and traceability of cell and gene therapies for more effective clinical studies and commercialization

A conversation with dangerous goods expert Jay Johnson